Fri, May 18, 2012
Thu, May 17, 2012
Wed, May 16, 2012
Tue, May 15, 2012
[ Tue, May 15th 2012 ] - Market Wire
CryoLife to Acquire Hemosphere
Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012

Seattle Genetics to Present at Bank of America Merrill Lynch Health Care Conference


//health-fitness.news-articles.net/content/2012/ .. merica-merrill-lynch-health-care-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


BOTHELL, Wash.--([ ])--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 1:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Geneticsa website at [ www.seattlegenetics.com ] in the [ Investors and News ] section.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].


Publication Contributing Sources